Development of a topical treatment for skin cancers

Offentlig prosjektsammendrag

In cooperation with Studies&Me, Coegin Pharma will conduct a double-blind placebo-controlled combined Phase I/II trial led by Professor Merete Hædersdal, responsible clinician at Bispebjerg Hospital in Copenhagen. Patients suffering from actinic keratosis will be recruited to the trial and treated with the drug candidate AVX001 in different doses. The purpose of the trial is to evaluate the product's safety and efficacy over a shorter duration of treatment, which further involves a digital, patient-centric approach. In March 2021, Coegin Pharma submitted an application to the Danish research ethics committee and the Danish Medicines Agency with the aim of starting a clinical trial in August 2021. The trial is expected to be completed in 2021, and results would then be presented in early 2022. The aim of the trial is to develop a new topical drug that meets all safety requirements and delivers a treatment effect that satisfies the patients’ need for safe, effective and convenient treatment of their disease.